News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>UBS Initiates Coverage on 3SBIO (01530.HK) w/ Rating Buy, TP $30; Key Licensing Agreement Validates R&D Capabilities
UBS released a research report initiating coverage on 3SBIO (01530.HK), with rating at Buy and a target price of $30.3SBIO's core products target hematology and autoimmune dise...
Reset
Send
The window will close in 5 seconds
<Research>UBS Initiates Coverage on 3SBIO (01530.HK) w/ Rating Buy, TP $30; Key Licensing Agreement Validates R&D Capabilities
Close
Recommend
6
Positive
12
Negative
3
 
SHORT SELL
 
STOCK INFO

UBS released a research report initiating coverage on 3SBIO (01530.HK)  +0.750 (+3.417%)    Short selling $115.61M; Ratio 16.378%   , with rating at Buy and a target price of $30.

3SBIO's core products target hematology and autoimmune diseases, according to the report. The broker believed that the recent record-breaking US$6.15 billion out-licensing agreement with Pfizer (PFE.US)      for SSGJ-707 (PD-1/VEGF bispecific antibody) reflects recognition of 3SBIO's strong R&D capabilities.

Related NewsCMBI Recommends 3 3SBIO/ BEIGENE/ INNOVENT BIO/ GIANT BIOGENE; CN Pharmas to Face ST Pullback Pressure
UBS was optimistic about the potential increase in peak overseas sales of SSGJ-707 and the value of other pipeline assets, and forecasted a CAGR of 11.7% for revenue and 12.1% for net profit from 2024 to 2034.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-27 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.